CSTL - Castle Biosciences Inc Stock Price, Fair Value and News

19.47USD+0.16 (+0.83%)Delayed as of 22 Apr 2024, 10:55 am ET

Market Summary

USD19.47+0.16

Delayedas of 22 Apr 2024, 10:55 am

0.83%

CSTL Stock Price

View Fullscreen

CSTL RSI Chart

CSTL Valuation

Market Cap

530.1M

Price/Earnings (Trailing)

-9.22

Price/Sales (Trailing)

2.41

Price/Free Cashflow

-27.54

CSTL Price/Sales (Trailing)

CSTL Profitability

Operating Margin

79.53%

Return on Equity

-14.69%

Return on Assets

-12.68%

Free Cashflow Yield

-3.63%

CSTL Fundamentals

CSTL Revenue

Revenue (TTM)

219.8M

Rev. Growth (Yr)

72.47%

Rev. Growth (Qtr)

7.52%

CSTL Earnings

Earnings (TTM)

-57.5M

Earnings Growth (Yr)

87.49%

Earnings Growth (Qtr)

62.64%

Breaking Down CSTL Revenue

52 Week Range

19.48

(Low)(High)

Last 7 days

-4.0%

Last 30 days

-5.4%

Last 90 days

0.5%

Trailing 12 Months

-19.9%

How does CSTL drawdown profile look like?

CSTL Financial Health

Current Ratio

6.2

CSTL Investor Care

Shares Dilution (1Y)

3.29%

Diluted EPS (TTM)

-2.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	152.2M	167.5M	192.0M	219.8M
2022	98.1M	110.2M	123.7M	137.0M
2021	68.0M	78.1M	86.3M	94.1M
2020	60.6M	62.5M	63.0M	62.6M
2019	27.8M	34.6M	45.7M	51.9M
2018	0	0	0	22.8M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Castle Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 12, 2024	maetzold derek j	sold	-6,450	20.35	-317	pres. & chief exec. officer
Apr 12, 2024	maetzold derek j	sold	-39,621	20.35	-1,947	pres. & chief exec. officer
Apr 12, 2024	maetzold derek j	sold	-6,471	20.35	-318	pres. & chief exec. officer
Apr 12, 2024	maetzold derek j	sold	-20,288	20.35	-997	pres. & chief exec. officer
Apr 08, 2024	bradbury daniel	sold	-15,564	20.453	-761	-
Apr 08, 2024	bradbury daniel	sold	-16,751	20.453	-819	-
Apr 08, 2024	bradbury daniel	sold	-16,771	20.453	-820	-

Which funds bought or sold CSTL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	89.27	116,746	240,593	-%
Apr 18, 2024	WASATCH ADVISORS LP	reduced	-1.54	593,876	56,506,600	0.30%
Apr 16, 2024	MCF Advisors LLC	unchanged	-	147	5,715	-%
Apr 15, 2024	Sound Income Strategies, LLC	sold off	-100	-5,395	-	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 05, 2024	GAMMA Investing LLC	added	476	2,195	2,680	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	unchanged	-	10,374	403,152	-%
Mar 26, 2024	Fairman Group, LLC	new	-	281	281	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-98.32	-37,419	820	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.53	7,227,500	31,538,800	-%

Are Funds Buying or Selling CSTL?

Are funds buying CSTL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CSTL

No. of Funds

Unveiling Castle Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	granahan investment management, llc	8.05%	2,166,471	SC 13G
Feb 13, 2024	principal global investors	5.89%	1,585,639	SC 13G
Feb 13, 2024	vanguard group inc	5.43%	1,461,481	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Jan 25, 2024	blackrock inc.	8.5%	2,283,199	SC 13G/A
Feb 09, 2023	wasatch advisors inc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	5.29%	1,392,724	SC 13G
Feb 03, 2023	blackrock inc.	8.1%	2,123,688	SC 13G/A
Feb 11, 2022	maetzold derek j	4.0%	1,022,068	SC 13G/A
Feb 10, 2022	wasatch advisors inc	-	0	SC 13G/A

Recent SEC filings of Castle Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	EFFECT	EFFECT
Apr 16, 2024	4	Insider Trading
Apr 12, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	ARS	ARS
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	DEFA14A	DEFA14A
Apr 08, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 04, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Castle Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	174.2B	23.9B	-6.45%	-5.19%	36.72	7.29	-10.33%	-33.23%
IDXX	39.6B	3.7B	-10.02%	-2.89%	46.84	10.81	8.72%	24.44%
A	38.9B	6.7B	-9.88%	-2.07%	31.47	5.78	-2.81%	-6.58%
DGX	14.2B	9.3B	0.58%	-10.70%	16.65	1.54	-6.38%	-9.73%
CRL	11.6B	4.1B	-15.49%	14.49%	24.52	2.82	3.86%	-2.39%
MEDP	11.4B	1.9B	-6.78%	97.59%	40.46	6.07	29.17%	15.26%
EXAS	11.1B	2.5B	-2.68%	-8.07%	-54.22	4.43	19.93%	67.26%
NTRA	10.3B	1.1B	-8.21%	57.21%	-23.68	9.51	31.99%	20.63%
MID-CAP
NEOG	2.5B	929.2M	-25.64%	-30.20%	1.6K	2.71	28.93%	111.61%
GH	2.0B	563.9M	-10.26%	-34.59%	-4.08	3.47	25.45%	26.76%
SMALL-CAP
CDNA	430.3M	280.3M	-16.97%	-3.59%	-2.26	1.53	-12.89%	-148.37%
ACRS	87.9M	31.2M	5.04%	-86.38%	-0.99	2.81	5.03%	-1.81%
AWH	43.1M	9.2M	0.29%	-35.85%	-2.58	4.71	11.85%	44.12%
APDN	5.8M	9.0M	-32.00%	-67.31%	-0.8	0.64	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Castle Biosciences Inc News

Latest updates

Castle Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	7.5%	66.00	61.00	50.00	42.00	38.00	37.00	35.00	27.00	25.00	23.00	23.00	23.00	17.00	15.00	13.00	17.00	18.00	15.00	11.00	9.00	11.00
Cost Of Revenue	9.8%	12.00	11.00	11.00	10.00	10.00	9.00	8.00	6.00	5.00	5.00	4.00	3.00	-	2.00	2.00	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	20.00	15.00	13.00	11.00	15.00	16.00	13.00	9.00	7.00	10.00
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	24.00	-	-	-	14.00	13.00	9.00	8.00	7.00	-
S&GA Expenses	-1.2%	44.00	45.00	45.00	47.00	38.00	37.00	37.00	30.00	25.00	23.00	21.00	18.00	15.00	12.00	10.00	11.00	10.00	7.00	7.00	6.00	-
R&D Expenses	0.5%	13.00	13.00	13.00	14.00	11.00	11.00	12.00	11.00	9.00	8.00	7.00	6.00	5.00	3.00	3.00	3.00	3.00	2.00	1.00	1.00	-
Interest Expenses	0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	0.00	1.00	1.00	1.00	1.00	1.00	2.00	1.00	-
Income Taxes	21.9%	0.00	0.00	0.00	0.00	0.00	-	-1.96	0.00	-1.77	-	0.00	-	0.00	-	-	-	0.00	-	-	-	-
Net Income	62.6%	-2.58	-6.90	-18.78	-29.20	-20.62	-20.25	-1.65	-24.62	-6.43	-11.79	-8.79	-4.28	-4.89	-4.59	-1.38	1.00	2.00	6.00	-1.27	-1.36	4.00
Net Income Margin	33.5%	-0.26*	-0.39*	-0.53*	-0.47*	-0.49*	-0.43*	-0.40*	-0.53*	-0.33*	-0.34*	-0.29*	-0.22*	-	-	-	-	-	-	-	-	-
Free Cashflow	478.6%	15.00	3.00	-7.82	-28.78	-7.79	-7.26	-10.41	-21.83	-3.67	-7.06	-7.35	-4.38	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	4.0%	453	436	425	427	447	458	458	444	463	434	436	437	439	210	202	120	120	113	33.00	22.00
Current Assets	5.7%	296	280	269	271	292	299	305	336	354	390	392	427	430	201	196	117	117	110	29.00	18.00
Cash Equivalents	8.3%	99.00	91.00	96.00	115	123	134	273	309	330	363	368	407	410	183	180	99.00	99.00	94.00	17.00	4.00
Inventory	37.7%	8.00	6.00	6.00	5.00	4.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00
Net PPE	-100.0%	-	22.00	21.00	18.00	14.00	13.00	11.00	9.00	10.00	9.00	8.00	8.00	7.00	7.00	5.00	3.00	2.00	2.00	2.00	2.00
Liabilities	23.6%	62.00	50.00	47.00	42.00	48.00	46.00	37.00	47.00	51.00	22.00	20.00	19.00	24.00	44.00	44.00	32.00	35.00	31.00	37.00	32.00
Current Liabilities	31.2%	48.00	36.00	34.00	30.00	36.00	32.00	28.00	40.00	25.00	21.00	19.00	18.00	21.00	30.00	28.00	15.00	15.00	9.00	12.00	7.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.00	15.00	17.00	19.00	22.00	24.00	25.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.00	10.00	8.00	6.00	3.00	1.00	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.00	15.00	17.00	19.00	22.00	24.00	25.00
Shareholder's Equity	1.4%	391	386	379	385	399	411	422	397	412	412	416	419	416	167	158	88.00	85.00	82.00	-	-
Retained Earnings	-1.2%	-218	-215	-208	-190	-160	-140	-120	-118	-93.77	-87.36	-75.57	-66.78	-62.50	-57.61	-53.02	-51.64	-52.21	-54.30	-60.12	-57.49
Additional Paid-In Capital	1.3%	609	602	588	575	560	552	542	516	505	499	491	485	478	224	211	140	137	137	10.00	1.00
Shares Outstanding	1.9%	27.00	27.00	27.00	27.00	27.00	26.00	26.00	25.00	25.00	25.00	25.00	25.00	-	-	-	-	-	-	-	-
Float	-	-	-	311	-	-	-	472	-	-	-	1,500	-	-	-	519	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	270.8%	18,587	5,012	-3,786	-25,439	-6,000	-5,224	-9,001	-21,430	-2,781	-6,133	-6,438	-3,631	-430	-2,955	13,501	-251	4,493	752	482	1,288	-
Share Based Compensation	-9.5%	11,802	13,043	12,849	13,525	9,923	9,196	8,783	8,419	6,851	5,210	4,766	4,913	2,961	2,118	1,653	1,577	713	229	139	168	-
Cashflow From Investing	21.0%	-7,672	-9,708	-15,387	16,584	-4,482	-134,150	-27,511	-402	-30,889	-923	-34,095	-750	-588	-1,904	-1,756	-500	-347	-166	-180	-244	-
Cashflow From Financing	-7426.7%	-3,297	45.00	226	728	-750	388	661	1,216	126	1,894	1,891	1,510	227,820	8,150	69,361	559	224	76,421	936	10,707	-

CSTL Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
NET REVENUES	$ 219,788	$ 137,039
OPERATING EXPENSES AND OTHER OPERATING INCOME
Cost of sales (exclusive of amortization of acquired intangible assets)	44,982	32,009
Research and development	53,618	44,903
Selling, general and administrative	180,152	143,003
Amortization of acquired intangible assets	9,013	8,266
Change in fair value of contingent consideration	0	(18,287)
Total operating expenses, net	287,765	209,894
Operating loss	(67,977)	(72,855)
Interest and other non-operating income	10,623	3,968
Interest expense	(11)	(17)
Loss before income taxes	(57,365)	(68,904)
Income tax expense (benefit)	101	(1,766)
Net loss	$ (57,466)	$ (67,138)
Loss per share, basic (in dollars per share)	$ (2.14)	$ (2.58)
Loss per share, diluted (in dollars per share)	$ (2.14)	$ (2.58)
Weighted-average shares outstanding, basic (in shares)	26,802	26,054
Weighted-average shares outstanding, diluted (in shares)	26,802	26,054

CSTL Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 98,841	$ 122,948
Marketable investment securities	144,258	135,677
Accounts receivable, net	38,302	23,476
Inventory	7,942	3,980
Prepaid expenses and other current assets	6,292	6,207
Total current assets	295,635	292,288
Long-term accounts receivable, net	1,191	1,087
Property and equipment, net	25,433	14,315
Operating lease assets	12,306	12,181
Goodwill and other intangible assets, net	117,335	126,348
Other assets – long-term	1,440	1,110
Total assets	453,340	447,329
Current Liabilities
Accounts payable	10,268	4,731
Accrued compensation	28,945	24,358
Operating lease liabilities	1,137	1,777
Other accrued and current liabilities	7,317	5,262
Total current liabilities	47,667	36,128
Noncurrent operating lease liabilities	14,173	11,533
Deferred tax liability	206	428
Other liabilities	25	90
Total liabilities	62,071	48,179
Commitments and Contingencies (Note 12)
Stockholders’ Equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2023 and 2022; no shares issued and outstanding as of December 31, 2023 and 2022.	0	0
Common stock, $0.001 par value; 200,000,000 authorized as of December 31, 2023 and 2022; 27,410,532 and 26,553,681 shares issued and outstanding as of December 31, 2023 and 2022, respectively.	27	27
Additional paid-in capital	609,477	560,409
Accumulated deficit	(218,371)	(160,905)
Accumulated other comprehensive income (loss)	136	(381)
Total stockholders’ equity	391,269	399,150
Total liabilities and stockholders’ equity	$ 453,340	$ 447,329

About Castle Biosciences Inc

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

CEO	Mr. Derek J. Maetzold
WEBSITE	https://castlebiosciences.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	582

Castle Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Castle Biosciences Inc? What does CSTL stand for in stocks?

CSTL is the stock ticker symbol of Castle Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Castle Biosciences Inc (CSTL)?

As of Fri Apr 19 2024, market cap of Castle Biosciences Inc is 530.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CSTL stock?

You can check CSTL's fair value in chart for subscribers.

What is the fair value of CSTL stock?

You can check CSTL's fair value in chart for subscribers. The fair value of Castle Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Castle Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CSTL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Castle Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CSTL is over valued or under valued. Whether Castle Biosciences Inc is cheap or expensive depends on the assumptions which impact Castle Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CSTL.

What is Castle Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, CSTL's PE ratio (Price to Earnings) is -9.22 and Price to Sales (PS) ratio is 2.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CSTL PE ratio will change depending on the future growth rate expectations of investors.